We assess site of expression, expression levels and turnover rates and factor in the PK properties of a biologics to test if meaningful PK/PD properties are obtained. The question we address is, can a meaningful amount of antibody inhibit your target for a sufficient long time to have an acceptable dosing interval in patients. Thus this activity allows you at a very early stage of the project to rank and select targets based on their kinetic properties and to lower the risk of developing a compound with unrealistic dosing requirements.
Further, potential secondary effects mediated by competition with endogenous ligands can be modelled for an early assessment of side effects.
Target assessment goes typically together with Format Selection and Compound Design.